BofA analyst Allen Lutz initiated coverage of Definitive Healthcare with a Neutral rating and $13 price target. Channel checks indicate the company is an industry leader in healthcare-focused business intelligence, Lutz tells investors in a research note. However, the analyst sees "cloudy" visibility with his industry survey suggesting some spending is "discretionary/project based."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DH:
